Purolite tripling resin capacity with manufacturing expansion

Purolite has cut the ribbon on the latest expansion at its chromatography resin production site in Wales, UK.

Dan Stanton, Editorial director

October 17, 2022

1 Min Read
Purolite tripling resin capacity with manufacturing expansion

Purolite has cut the ribbon on the latest expansion at its chromatography resin production site in Wales, UK.

Purolite manufactures resins out of agarose, a material originating from red seaweed. The firm turns the agarose into tiny beads, typically between 35 and 200 microns in size, which are then used as a raw material by biomanufacturers to purify monoclonal antibody therapies.

The expansion at the Llantrisant site – located about 20km northwest of Cardiff – will treble Purolite’s capacity and is part of a multi-million-dollar global investment in the company undertaken by Ecolab, which acquired the firm last year for $3.7 billion.

Purolite-3-300x200.jpg

“The opening of our new Customer Experience Centre is another celebratory moment for the Purolite team here in Wales,” said Hayley Crowe, SVP and general manager of Purolite.

“Our site-wide facilities expansion is strategically designed to help accelerate Purolite’s ability to provide customers throughout the world with high quality resin products and short lead times, enabling our customers to deliver life-saving drugs faster.”

The ribbon-cutting ceremony took place last Thursday with His Majesty’s Lord-Lieutenant of Mid Glamorgan and Deputy Mayor Wendy Lewis of Rhondda Cynon Taf Council among those in attendance.

Read more: ‘For resins, supply chain resilience is key, says Purolite’

About the Author

Dan Stanton

Editorial director

Journalist covering the international biopharmaceutical manufacturing and processing industries.
Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like